Purpose: To compare standard radiotherapy field (SRTF) with whole abdomen irradiation (WAI), used in conjunction with adjuvant chemotherapy following curative surgery in patients with gastric cancer. Methods and Material: Ninety patients were included in the study and divided into two treatment arms. In the first treatment arm, SRTF, including 45 Gy radiation to the primary tumor and regional lymph nodes, was performed in 45 patients. In the second treatment arm, a total of 45.2 Gy RT was delivered; 20 Gy to the whole abdomen followed by 25.2 Gy RT to the tumor and regional lymph nodes, in 45 patients. An intravenous bolus dose of 250 mg/m 2 /week 5-fluorouracil (5-FU) was administered concomitantly with RT in both treatment arms. Patients who completed concomitant chemoradiotherapy, received adjuvant treatment, including 4 cycles of 5-FU (425 mg/m 2 ) and folinic acid (20 mg/m 2 ) in 4 week intervals. Results: Median age was 56 years (range: 22-81), 89% of the patients (n = 80) had serosal involvement, 78% (n = 70) were node positive. The rate of hematological (40% vs. 16%, p = 0.010) and gastrointestinal toxicities (80% vs. 53%, p = 0.010) were higher, and performance loss (60% vs. 29%, p = 0.003) was greater in the second treatment arm. Number of patients who experienced Grade 3 and Grade 4 gastrointestinal toxicities (especially diarrhea) were higher in the second treatment arm (4% vs. 16%, p = 0.049). The median follow-up was 19 months (range: 7-96). The median 5-year survival was 29% and 17%, locoregional control was 30% and 25%, and disease-free survival was 27% and 16% in the first and second treatment arms, respectively. There was no significant difference between the treatment groups in terms of survival, locoregional control and disease-free survival rates (p > 0.05). Conclusion: Whole abdomen irradiation was not found to be superior to standard field radiotherapy used in conjunction with adjuvant chemotherapy in gastric cancer.
INTRODUCTION
Gastric cancer is the fourth most frequent malignancy and the second leading cause of cancer-related mortality.
1) The primary treatment method for gastric carcinoma is surgery; however, as most patients are diagnosed in advanced stages of the disease, the success rate of curative treatment is often low.
2) Overall survival is associated with the stage of the cancer and is significantly reduced in advanced stages. 3, 4) The site of failure following surgical treatment is usually in the locoregional area which involves the tumor bed. Local failure is observed in 38%-85% of patients. The failure site may not be limited to the tumor bed alone, and may be within the abdomen in 9%-54% of patients. [5] [6] [7] Attempts to reduce the recurrences by increasing the size of the surgery have unfortunately failed. Moreover in large randomized studies, it has been demonstrated that extended lymphadenectomy does not contribute to survival and increases morbidity. [8] [9] [10] It has been demonstrated that adjuvant chemotherapy (CT) or radiotherapy (RT) alone do not improve the prognosis of high-risk gastric cancer patients, while chemoradiotherapy (CRT) reduces locoregional failure and improves survival in patients with upper gastrointestinal malignancies. 11, 12) It is likely that whole abdomen irradiation (WAI) used in the management of ovarian and endometrial cancers may provide a benefit in the local control of gastric cancers with high rates of intra-abdominal failure. 13, 14) Classic clinical studies have shown that radiation doses of 45-50 Gy can control subclinical disease in 90% of the cases. 15 ) While these doses can safely be administered to the tumor bed limited to the upper abdomen, they cannot be administered to the whole abdomen. It should be noted, however, that lower tolerable doses are not ineffective and may decrease the recurrence rates. Moreover, effectiveness may be increased by the concomitant administration of 5-fluorouracil (5-FU) at low doses as a radiosensitizing agent. [16] [17] [18] There is no study which has been compared standard field RT (SFRT) and WAI in patients with gastric cancer. The aim of this study was to compare locoregional control, diseasefree survival, overall survival, and treatment-related toxicity for two different RT schemes (SFRT and WAI) used concomitantly with CT following curative surgery in patients with gastric cancer.
MATERIALS AND METHODS
Ninety patients with gastric cancer who had curative surgery between February 2002 and December 2005 were included in this retrospective study. The study was approved by the institutional review board.
Inclusion criteria
Following total or subtotal gastrectomy, 90 patients with gastric cancer with serosal and/or LN involvement and/or (+)/close surgical margins, but without distant metastasis, were included in the study. Patients were staged according to the American Joint Committee for Cancer Staging System (AJCC) 2002. 19) Inclusion criteria were Eastern Cooperative Oncology Group (ECOG) performance status 0-2, adequate renal function (serum creatinine level ≤1.5 mg/dl, and creatinine clearance ≥60 ml/minute), liver function (serum total bilirubin level ≤1.6 mg/dl, and serum transaminases levels <2.5 times the upper limit of normal), and bone marrow (hemoglobin >10 mg/dl, leukocyte count ≥4000/μL, and platelet count ≥100,000/μL). Exclusion criteria were severe heart disease, such as coronary artery disease, congestive heart failure, and prior radiotherapy/chemotherapy.
Treatment plan
The patients were divided into two different RT arms. The selection was made according to the physician's preference, and generally the patients who have pathologically proven peritonitis carcinomatosa were put into the second treatment arm. Patients in both arms were treated with the same CT scheme. An intravenous bolus dose of 5-FU (250 mg/m 2 / week) was concomitantly administered during RT. Within 2-4 weeks of completion of RT, 4 cycles of intravenous bolus 5-FU (425 mg/m 2 ) and folinic acid (20 mg/m 2 ) were administered consecutively between 1-5 days at 4 week intervals. Two-Dimentional treatment planning system was used and RT was delivered by a linear accelerator device including 6-18 MeV photons. In the first treatment arm, SFRT was performed in 45 patients to the primary tumor bed (at proximal gastric and cardia tumors, upper border of RT field is included at least 2/3 left hemidiaphragm, lower border is passed under L3 vertebrae; at distal gastric tumors, the upper border of the RT field is top of the diaphragm, and lower border is at the middle of the L4 vertebrae) and regional lymph nodes (perigastric-celiac-hepatic-splenic-pancreaticoduodenal and paraaortic lymph nodes area) at a total dose of 45 Gy in 5 weeks (1.8 Gy/day; 5 days/week/25 fractions). At the beginning of the treatment an IV contrast was administered to show kidneys and be protected half of it in the left and almost totally in the right, at proximal and cardia located gastric tumors. In distal gastric cancers, 1/3 right and 2/3 left kidney was protected by custom-made lead-blocks. In the second treatment arm, following WAI (20 Gy, 1 Gy/day; 5 days/week/20 fractions), RT (25.2 Gy, 1.8 Gy/day; 5 day/ week/14 fractions) was delivered to the classical RT field as in the first treatment arm, making a total dose of 45.2 Gy RT in 7 weeks in 45 patients. In the WAI arm, the daily dose was limited to 1 Gy due to the presence of radiation sensitive organs, such as small and large intestines, and the total dose was limited to 20 Gy due to the presence of dose-limiting anatomical structures, such as liver and kidney. All patients were treated by AP-PA fields, the dose was prescribed to isocentre, and portal imaging films were taken in every weeks of treatment.
Assessment
Patients in both treatment arms were evaluated in terms of locoregional and distant control, disease-free survival, overall survival, and concomitant CRT-related adverse effects. Acute CRT-related adverse events were graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 2.0. 20) The time from the date of surgical resection to death or final visit was recorded as overall survival, the time from the date of surgical resection to the development of locoregional recurrence or distant metastasis was recorded as the disease-free survival, and the time from the date of surgical resection to locoregional recurrence as locoregional control.
Patient follow-up after treatment
Patients who completed concomitant CRT and adjuvant CT schemes were seen at follow-up visits monthly in the first 6 months, every 3 months between 6 months and 1 year, and then every 6 months afterwards. Performance status, treatment-related adverse effects, whole blood count, abdominal ultrasonography and tomography, and liver and renal function tests were assessed in all patients at followup visits. Endoscopy was performed once yearly or in case of suspected locoregional failure.
Statistical analysis
SPSS, version 15.0, was used for statistical analysis. The treatment arms were compared in terms of age, gender, gastrectomy type, initiation time of adjuvant treatment following resection, location of the primary tumor, stage, surgical margin, pathologically proven peritonitis carcinomatosa and lymphadenectomy status by the Mann-Whitney U and chisquare tests (χ 2 ). Locoregional control, distant control, and 
RESULTS

Patient characteristics
Clinical characteristics of the patients are presented in Table 1 . The median age was 56 years (range, 22-81 years), 70% were male (n = 63), 59% had total gastrectomy (n = 53), 70% had diffuse type gastric cancer (n = 63), cancer was located in the antrum in 72% (n = 65), 89% had serosal involvement (n = 80), 78% were node-positive (n = 70), 59% had Stage III disease (n = 53), D2 dissection was performed in 15% (n = 13) and 18% (n = 16) were cases with positive surgical margin.
There was no significant difference between the two treatment arms in terms of age, gender, the location and histopathology of the primary tumor, T and N stage, surgical margin status, lymphadenectomy status, stage of the disease, completion of CRT/CT, and time until treatment initiation. There was a significant difference between the two groups in terms of gastrectomy type and pathologically-proven peritonitis carcinomatosa (p = 0.03).
Treatment characteristics and toxicity
Among patients in the first treatment arm, 96% (n = 43) completed the concomitant CRT scheme, while the rate was 92% (n = 41) in the second treatment arm. Overall, 25% (n = 11) and 24% (n = 10) of the patients failed to complete the adjuvant CT in the first and in the second treatment arms, respectively. The rate of completeness of CRT: At first arm, 96 % (n = 43) and at second arm, 92% (n = 41), and the difference between two arms was not statistically significant (p = 0.26). The rate of completeness of consolidation chemotherapy: At first arm, 76% (n = 34), and at second arm: 76% (n = 35), and the difference between two arms was not statistically significant (p = 0.13). Median follow-up time was 20 months (range, 7-96 months) at first arm, and 15 months (range, 7-85 months) at second arm (p = 0.62). When treatment-related toxicities during concomitant CRT were compared in the two treatment arms, the most frequent grade I-II toxicities were hematological such as neutropenia, anemia and thrombocytopenia, and the other toxicities observed were gastrointestinal such as nausea and vomiting, diarrhea, and performance loss. The following toxicities were significantly higher in the second treatment arm: hematological toxicity (40% vs. 16%, p = 0.010), gastrointestinal toxicity (80% vs. 53%, p = 0.010), and performance loss (60% vs. 29%, p = 0.003). Grade III and IV gastrointestinal toxicities (especially diarrhea) were significantly higher in the second treatment arm (16% vs. 4%, p = 0.049; Table 2 ). Hepatic, renal, and gastric toxicity were not seen.
Locoregional and distant control
Locoregional recurrence (LRR) was noted in 65% of the patients (n = 58); in 67% (n = 30) and 62% (n = 28) of the patients in the first and in the second treatment arm, respectively (Table 3 ). No significant difference was found between the two treatment arms in terms of locoregional control (p = 0.70).
Distant recurrence was noted in 29% of the patients (n = 26). Distant metastasis was noted in 33% of the patients (n = 15) in the first and in 24% of the patients (n = 11) in the second treatment arm (Table 3 ). No significant difference was found between the two treatment arms in terms of distant control (p = 0.32). The most frequent distant metastasis was noted in the liver in both treatment arms (13% and 17%, respectively).
Survival
The median duration of follow-up was 19 months (range, 7-96 months). Five-year survival was 23%, locoregional The median 5-year survival was 29% and 17%, locoregional control was 30% and 25%, and disease-free survival was 27% and 16% in the first and second treatment arms, respectively. The median survival was 22 months vs. 15 months, locoregional control was 15 months vs. 16 months, and disease-free survival was 12 months vs. 14 months in the first and second treatment arms, respectively. The survival curves are presented in Fig. 1-3 . Although overall survival rates in the first treatment arm was higher than the second treatment arm, the difference was not statistically significant (p = 0.13). Despite a tendency of higher locoregional control and longer disease-free survival rates in the first year in the WAI arm, the tendency was lost in later years (p = 0.89 and p = 0.46, respectively).
In univariate and multivariate analyses, no significant difference was observed in the overall survival rate, locoregional control, and disease-free survival rates between the treatment groups in terms of age, gender, serosal involvement, lymph node involvement, stage of the disease, surgical margin, lymphadenectomy status, gastrectomy type and pathologically-proven peritonitis carcinomatosa (p > 0.05). But, the pathologically-proven peritonitis carcinomatosa (hazard ratio, 1.74; 95% confidential interval (CI): 1.05-2.89; p = 0.031) has been found a statistically significant variable for overall survival in Cox regression analysis.
DISCUSSION
As the symptoms of gastric cancer are non-specific, it is often diagnosed in the locally advanced stage when serosal and/or lymph node (LN) involvement or distant intraabdominal spread from the tumor bed occurs. Primary treatment is surgical resection. The 5-year survival after surgery is < 30% in patients with serosal involvement only and <15% in those with serosal and nodal involvement. 7) Locoregional failure in the tumor bed, regional lymph nodes, stump, or anastomosis is approximately 60% in patients with nodal or serosal involvement. Extra-regional disease most often starts from the peritoneum and spreads to distant lymph nodes, and is intra-abdominal. 5) On second-look laparotomy, locoregional failure has been found in 67%, peritoneal seeding in 42%, and distant metastasis in 22% of the patients. 8) Due to failure to demonstrate any beneficial effect of adjuvant CT or RT following surgery on survival in previous randomized studies, combination chemo-radiotherapy treatments (CRT) have been attempted and shown to reduce locoregional failure and improve survival in upper gastrointestinal malignancies.
12) Moertel et al. 21) have compared RT alone and concomitant RT and 5-FU (n = 48), and found that the median survival was 13 months in the CRT arm and 6 months in the RT alone arm, and the 5-year overall survival rates were 23% vs. 4%, respectively. 21) Macdonald et al. 22) (Intergroup 0116) randomized 556 patients with stage IB-IV gastric carcinoma who had curative resection (R0) and 10% of whom had also D2 dissection into 2 treatment arms and compared the group receiving CT plus CRT after surgery with the group who had surgery alone. They found that both 5-year overall survival rates of 40% vs. 28.4% (36 months vs. 27 months) and disease-free survival rates of 31% vs. 25% were higher in the combined treatment arm compared to surgery alone. Grade 3 and 4 toxicities were also greater in the CRT arm compared to the surgery alone group (41% vs. 32%) and treatment-related toxic death has been reported to be 1% in the CRT arm. Therefore, combined treatment has become a standard procedure due to the benefits for survival, despite the increased number of adverse events. Kim et al. 23) have compared adjuvant CRT and surgery in patients with D2 dissection and showed a significant difference in favor of CRT in terms of overall survival (95.3 months vs. 62.6 months) and disease-free survival (75.6 months vs. 52.7 months). Despite these studies, there is no standard approach regarding the use of CRT in terms of RT field dimensions, daily and total dose and the chemotherapeutic agent.
In the current study, adjuvant CT has been administered following concomitant CRT in T 3-4 and/or lymph nodepositive and/or surgical margin (+)/close gastric cancer patients after surgery. Although the 5-year overall survival, which was 19 months in the entire study population, was higher compared to the results of Moertel et al., 21) it was lower than the recently reported results of Macdonald et al. 22) and Kim et al.. 23) The differences may be associated with differences in stage, gastrectomy type, dissection, concomitant 5FU dose and administration, and RT dose. Grade 3 and 4 toxicity rates related to concomitant CRT were within an acceptable range and there were no deaths. Our RT dose was higher compared to Moertel et al., 21) and was the same as used by Macdonald et al. 22) and Kim et al., 23) thus the difference may be explained by the differences in CT dose and administration (Table 4 ).
There have been two studies investigating WAI in the adjuvant treatment of gastric cancer. 24, 25) Following resection in 52 patients of whom 46% were stage II, Baeza et al. 24) administered a total of 45 Gy RT (21 Gy to whole abdomen, then 24 Gy to the tumor bed) concomitant with 5-FU (400-500 mg/m 2 ) on the first and last 5 days of RT, then a 200-300 mg/m 2 intravenous bolus or continuous infusion throughout RT and found a 5-year overall survival of 54% (65% in N1 cases, 31% in N2-3 cases, 44% in patients with serosal involvement, and 69% in patients without serosal involvement). In one study conducted in 10 lymph nodepositive patients after surgery, Kundel et al. 25 ) administered a single dose of 6 Gy RT from two fields (anterior and posterior) 3 weeks after completion of 6 cycles of FU (1000 mg/m 2 ) and cisplatin (100 mg/m 2 ) CT. They reported that the most frequent toxicity was grade I-II nausea and vomiting and the median survival was 20 months. After 13.5 months of follow-up, locoregional recurrence was noted in 3 patients, and distant metastasis was noted in 6 patients (4 in the liver). When SRTF and WAI were compared in the current study, no significant difference was observed in terms of the 5-year locoregional control (30% vs. 25%), disease-free survival (27% vs. 16%), and overall survival (29% vs. 17%; p > 0.05). It should be noted, however, that high rates of total gastrectomy in the WAI group might have influenced the results. Although the toxicity results in the WAI group were within acceptable limits, gastrointestinal toxicity in particular was more common compared to the standard RT group.
Except the CT dose, our method of WAI was similar to that utilized in the Baeza et al. study, 24) while Kundel et al. 25) used a completely different method of single dose administration. The lower 5-year locoregional control, disease-free survival, and overall survival results in the WAI arm (25%, 17%, and 16%, respectively) might be due to the concomitant 24) vs. 89% in the current study and 46% stage III disease in the Baeza et al. 24) study vs. 59% in ours]. Despite these limitations, we believe that our results are valuable in terms of comparing two different RT protocols in a retrospective fashion since there was no significant difference between the two treatment arms in terms of prognostic factors of potential influence and the same doses of CT was used in both arms. We have been using the same standard RT field and concomitant In conclusion, we assumed that WAI may preclude locoregional recurrences of gastric cancer duo to involving of all lymphatics and suspicious dissemination of primary surgery.
But we failed to demonstrate any contributory effect of WAI combined with CT on locoregional control, disease-free survival, and overall survival of patients with gastric cancer with serosal and/or nodal involvement compared with standard adjuvant concomittant CRT. This may partly depend on selection of patients who have poor prognostic characteristics, or the dose/dose rate of WAI may be ineffective. So, we suggest the standard RT field and dose untill, WAI is dem- 
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